RA Capital Healthcare Fund LP, whose investments are overseen by RA Capital Management, L.P., moved to sell a sizeable block of Vor Biopharma Inc. (NASDAQ: VOR) common stock in April 2026, disposing of 630,374 shares in total for approximately $10,174,787.
The dispositions were recorded on two separate dates. On April 17, 2026, the fund sold 458,411 shares at a weighted average price of $16.28 per share. Those trades were executed in multiple tranches with individual prices ranging from $15.95 to $16.85.
Three days later, on April 20, 2026, an additional 171,963 shares were sold at a weighted average price of $15.77 per share. Transaction prices on that date varied between $15.75 and $16.00.
Following the April activity, RA Capital Healthcare Fund LP holds 2,567,245 shares of Vor Biopharma common stock. The shares sold by the fund had been held indirectly by the fund and managed through RA Capital Management, L.P., which acts as the fund's investment manager.
Company governance ties to RA Capital are noted in regulatory filings: Peter Kolchinsky and Rajeev Shah, managing members of the Adviser’s general partner, are listed as directors and ten percent owners of Vor Biopharma.
The stock was trading at $15.17 at the time of reporting, a price point that underscores the recent volatility in VOR shares. Over the past 52 weeks the stock has ranged from a low of $2.62 to a high of $65.80.
Clinical and strategic developments
Vor Biopharma has been reorienting its clinical focus toward autoimmune disease therapies after moving away from an earlier oncology cell therapy emphasis. Most notably, the company recently dosed the first patient in a global Phase 3 trial for Sjögren’s disease. That study is expected to enroll approximately 250 patients and will measure change in disease activity over a 48-week period.
The company also licensed telitacicept from RemeGen. Telitacicept is already approved in China for multiple conditions and is undergoing filings for additional diseases.
Analyst reaction and financing context
Analysts have revised their outlooks for Vor Biopharma amid the strategic pivot and recent equity raises. Stifel cut its price target from $55 to $40, citing revised financing assumptions after the company raised over $330 million in equity capital, while maintaining a Buy rating. Jefferies initiated coverage with a Buy rating and a $50 price target, pointing to the company’s shift into autoimmune diseases. H.C. Wainwright trimmed its price target modestly from $32 to $31 and continues to carry a Buy rating.
Separately, InvestingPro analysis included in filings indicates that VOR appears undervalued at current levels and that more comprehensive Pro Research Reports are available for investors seeking deeper analysis across VOR and more than 1,400 U.S. equities.
Context and takeaway
The April sell-down by RA Capital Healthcare Fund LP reduced the firm’s exposure but left it with a multi-million share position. The transactions occurred in a market environment that has exhibited wide price swings for VOR. At the same time, Vor Biopharma is progressing a pivotal autoimmune program and making strategic licensing moves, developments that analysts continue to weigh differently as they adjust price targets and ratings.